Mesoblast furnishes 6-K with 2025 Annual Report and governance docs

Rhea-AI Filing Summary

Mesoblast Limited furnished a Form 6-K detailing the availability of key shareholder materials filed with the Australian Securities Exchange. The submission includes the company’s Annual Report to Shareholders, a Notice of Annual General Meeting, and an Appendix 4G with Corporate Governance Statement, each attached as Exhibits 99.1, 99.2, and 99.3 and incorporated by reference.

Mesoblast reports as a foreign private issuer and files annual reports under Form 20-F. The filing identifies Australia as the jurisdiction of incorporation and lists the principal office at Level 38, 55 Collins Street, Melbourne 3000, Australia. The report was signed by Company Secretary Niva Sivakumar on October 28, 2025.

FAQ

What did Mesoblast (MEOBF) submit on this Form 6-K?

It furnished its Annual Report to Shareholders, a Notice of Annual General Meeting, and an Appendix 4G with Corporate Governance Statement as Exhibits 99.1, 99.2, and 99.3.

Which exhibits are included in the Mesoblast (MEOBF) 6-K?

Exhibit 99.1: Annual Report to Shareholders; Exhibit 99.2: Notice of Annual General Meeting; Exhibit 99.3: Appendix 4G and Corporate Governance Statement.

When were the Mesoblast (MEOBF) exhibits dated?

All exhibits are dated October 28, 2025.

Does Mesoblast (MEOBF) file on Form 20-F or 40-F?

It files annual reports under cover of Form 20-F.

Who signed the Mesoblast (MEOBF) submission?

Company Secretary Niva Sivakumar signed the report on October 28, 2025.

Where is Mesoblast (MEOBF) incorporated and where is its principal office?

It is incorporated in Australia with principal offices at Level 38, 55 Collins Street, Melbourne 3000, Australia.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 10/27/2025 - 07:56 PM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of October 2025

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On October 28, 2025, Mesoblast Limited filed with the Australian Securities Exchange its Annual Report to Shareholders, which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

On October 28, 2025, Mesoblast Limited filed with the Australian Securities Exchange a Notice of Annual General Meeting, which is attached hereto as Exhibit 99.2, and is incorporated herein by reference.

On October 28, 2025, Mesoblast Limited filed with the Australian Securities Exchange its Appendix 4G and Corporate Governance Statement, which is attached hereto as Exhibit 99.3, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited

/s/ Niva Sivakumar

Niva Sivakumar

Company Secretary

Dated: October 28, 2025

INDEX TO EXHIBITS

Item
99.1						Annual Report to Shareholders of Mesoblast Ltd, dated October 28, 2025.
99.2						Notice of Annual General Meeting of Mesoblast Ltd, dated October 28, 2025
99.3						Appendix 4G and Corporate Governance Statement of Mesoblast Ltd, dated October 28, 2025